Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies

ClinicalTrials.gov ID: NCT01427881

Public ClinicalTrials.gov record NCT01427881. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 20, 2026, 2:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation

Study identification

NCT ID: NCT01427881
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Fred Hutchinson Cancer Center; Other
Enrollment: 43 participants

Conditions and interventions

Conditions

Interventions

allogeneic hematopoietic stem cell transplantation Procedure
busulfan Drug
cyclophosphamide Drug
cyclosporine Drug
fludarabine phosphate Drug
peripheral blood stem cell transplantation Procedure
total-body irradiation Radiation

Procedure · Drug · Radiation

Eligibility (public fields only)

Age range: Up to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 31, 2011
Primary completion: May 31, 2014
Completion: Jun 30, 2015
Last update posted: May 18, 2017

2011 – 2015

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium	Seattle	Washington	98109	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01427881, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 18, 2017 · Synced May 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01427881 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →